Pharmaceutical News

RSS

Public Health Advisory for medical professionals with patients on anti-depression medication

On Monday, March 22, 2004 the Food and Drug Administration issued a Public Health Advisory for medical professionals to monitor for signs of suicidal ideation in individuals who have recently started taking anti-depression medication or have had a recent change in dosage, especially for children who are taking these medications. Antidepressant medications involved in this warning include: Prozac (Fluoxetine), Zoloft, Paxil, Luvox, Celexa, Lexapro, Wellbutrin, Effexor,, Serzone, and Remeron.

25 Apr 2004

7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of avoidable medication mistakes

Some 7,000 U.S. hospital patients die each year and more than 750,000 are injured as a result of medication mistakes. These errors have many causes, and many potential solutions, according to a Rutgers-Camden nursing scholar who has studied the topic extensively.

23 Apr 2004

Helping doctors to prescribe the right medication

With so many new drugs on the market to treat arthritis and related disorders, how do doctors know which ones to use?

23 Apr 2004

Canadian doctors oblivious to costs of prescribed drugs

For the most part, family physicians in British Columbia aren't even close when they guess the costs of the treatments and tests they prescribe for their patients, according to a new study published in the journal Canadian Family Physician.

23 Apr 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Idebenone continues to show promise in treating Friedreich’s ataxia (FA)

Idebenone, a compound similar to coenzyme Q10, continues to show promise in treating the heart complications of Friedreich's ataxia (FA), notes correspondence published in the Feb. 10 issue of Neurology.

23 Apr 2004

IVAX announces intention to revise offer for Polfa Kutno

IVAX Corporation announced today a revised offer to acquire the shares of Kutnowskie Zaklady Farmaceutyczne Polfa SA (“Polfa Kutno”). IVAX intends to acquire, in exchange for IVAX stock, up to 100%, but not less than 75% of the shares of Polfa Kutno for a price of 340 PLN per share.

23 Apr 2004

New steps to prevent drug card fraud

Centers for Medicare & Medicaid Services Administrator Mark B. McClellan, M.D., Ph.D. today announced efforts that CMS is undertaking to strengthen oversight of the Medicare-approved Discount Drug Card Program.

23 Apr 2004

Research may offer potent vaccines for viruses such as HIV and West Nile

Researchers at La Jolla Institute for Allergy & Immunology (LIAI) have identified two molecules (TL and CD8aa) that cooperate to trigger immune cells to develop into long-lived memory cells to fight recurring infections. This finding may have important implications for the future development of longer lasting and more potent vaccines for viruses such as HIV and West Nile.

23 Apr 2004

SSRI antidepressants may be unsuitable for children

A UK study in this week's issue of THE LANCET suggests that reliance on published studies alone to guide the treatment of childhood depression could be inappropriate. A systematic review including published and unpublished data shows that only one drug, fluoxetine (Prozac), was not associated with negative outcomes for children with depression.

22 Apr 2004

Access to effective malaria treatment for Africa threatened by drug shortages

Widespread use of a new fast-acting and potent treatment for malaria is finally on the horizon in Africa, where malaria is the number one killer of children.

22 Apr 2004

Clinical trial of curcumin in people with cystic fibrosis

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that it is funding a clinical trial of curcumin in people with cystic fibrosis (CF).

22 Apr 2004

SkyePharma delivery technologies for respiratory drugs to feature at two international conferences

SkyePharma PLC has announced that its proprietary delivery technologies for respiratory drugs will be presented later this month at two international conferences, one in the UK and one in America.

22 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

FDA approval for drug to treat attention deficit hyperactivity disorder

McNeil Consumer & Specialty Pharmaceuticals has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the use of CONCERTA® (methylphenidate HCl) CII Extended-release Tablets in adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) and to expand labeling to include a 72 mg dosing regimen.

22 Apr 2004